OVID stock forecast, quote, news & analysis
Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders... Show more
Why Ovid Therapeutics (OVID) Is Up +35% in the Last 30 Days
Key Takeaways
- OVID stock surged +35% over the past 30 days, driven by positive clinical data for OV329 and Phase 1 clearance for OV4071 announced on March 18, 2026.
- Over the past quarter, the stock rose +79%, reflecting sustained momentum from pipeline advancements and a $60 million private placement financing.
- Earnings beat in Q4 2025 with EPS of $0.06 versus expected -$0.10 fueled initial rally, alongside analyst price target increases.
- High trading volumes accompanied price spikes, indicating strong market sentiment toward the company's epilepsy and CNS disorder pipeline.
- Broader biotech sector trends supported gains, but company-specific catalysts dominated the price movement.
Ovid Therapeutics (OVID) Company Overview and Market Position
Ovid Therapeutics Inc. is a biopharmaceutical company focused on developing small molecule medicines for brain disorders, particularly epilepsies and seizure-related neurological conditions caused by excess neural excitability. Its core business model centers on advancing a pipeline of novel therapies targeting unmet needs in central nervous system (CNS) diseases, including OV329, a next-generation GABA-aminotransferase (GABA-AT) inhibitor, and OV4071, an oral direct activator of potassium-chloride cotransporter 2 (KCC2). The company generates revenue from royalty agreements and collaborates with partners like AstraZeneca and Lundbeck.
In the competitive biotech landscape, Ovid positions itself with potential first-in-class mechanisms for treatment-resistant seizures, tuberous sclerosis complex (TSC), and infantile spasms. Its fundamentals, including a cash position of $90.4 million as of December 31, 2025 extended by recent financing, provide runway for clinical trials, directly supporting recent stock price appreciation amid positive data readouts.
Ovid Therapeutics (OVID) Stock Price Performance: Last 30 Days vs. Quarter
Over the last 30 days, OVID stock climbed from a close of $2.13 to $2.88, marking a +35% gain. The movement was volatile and trend-driven, with a sharp spike on March 18 following pipeline updates, reaching highs near $2.62 before consolidating and resuming upward momentum in early April amid high volumes exceeding 6 million shares on key days.
For the past quarter, the stock advanced from $1.61 to $2.88, a robust +79% increase. Performance featured steady uptrend with intermittent volatility tied to news events, outperforming broader biotech indices. The 50-day moving average rose to around $1.90, confirming bullish price action.
What Drove OVID Stock Price in the Last 30 Days
The primary catalyst was Ovid's March 18, 2026 announcement of favorable topline safety, tolerability, and pharmacokinetics data from the OV329 7 mg dose cohort in Phase 1 trials, alongside expansion into TSC seizures and infantile spasms. Concurrently, the company received Phase 1 clearance for OV4071 and reported Q4 2025 financials, beating EPS estimates at $0.06 versus -$0.10 expected and revenue of $0.72 million against $0.06 million forecast.
A $60 million private placement PIPE financing, priced that day, bolstered cash to support OV329 expansion, extending runway into 2028-2029. These events triggered massive volume of over 40 million shares on March 18, propelling the stock +14% that day alone. Analyst reactions followed, with HC Wainwright raising its target to $4 and B. Riley initiating Buy at $9, shifting sentiment positively. Sector tailwinds in neurology biotech amplified the rally.
What Drove OVID Stock Performance Over the Last Quarter
The quarter's +79% rise built on accumulating positive narratives around Ovid's pipeline. March's major updates provided the strongest thrust, but earlier momentum stemmed from ongoing Phase 1 progress in OV329 and KCC2 activators. Q4 earnings highlighted $90.4 million cash reserves and royalty revenue growth to $7.3 million annually, reducing dilution fears.
Biotech market recovery, favorable interest rate expectations, and investor focus on CNS innovation supported gains. Institutional interest grew post-financing, with leadership transitions earlier stabilizing operations. Cumulative impact of clinical milestones and financial strengthening outweighed prior setbacks, driving sustained outperformance.
Trending AI Robots
Tickeron’s Trending AI Robots page showcases the top-performing AI trading bots from its extensive library of hundreds of algorithms actively trading thousands of tickers across various markets. This curated section highlights bots with the strongest recent performance, relevance to current market trends, and diversity in strategies—ranging from short-term scalping to long-term trend following, momentum plays, and mean reversion approaches. Each bot displays key metrics like win rate, average return, Sharpe ratio (a measure of risk-adjusted performance), and trade frequency, helping users identify tools suited to their risk tolerance and timeframe. Whether focusing on equities, ETFs, or forex, these trending robots offer data-driven insights for automated trading. Explore the page to discover bots potentially signaling opportunities in volatile biotech names like OVID and optimize your portfolio with AI precision.
OVID Stock Forecast Drivers: What Investors Should Watch Next
Investors should monitor upcoming KCC2-focused R&D Day on April 14, 2026, for deeper insights into OV4071 and related compounds targeting psychosis in Parkinson's and schizophrenia. Progress in OV329 Phase 1 trials, including data from higher doses and pediatric formulations for TSC and infantile spasms, remains critical.
Future earnings releases will detail cash burn and milestone progress, alongside any partnership developments or regulatory feedback. Macro factors like biotech funding environment, interest rates, and FDA policy shifts could influence sentiment. Risks include clinical setbacks or dilution, while catalysts encompass additional data readouts, analyst updates, and sector M&A (mergers and acquisitions) activity in neurology.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations
OVID's Indicator enters downward trend
The Aroon Indicator for OVID entered a downward trend on June 22, 2026. Tickeron's A.I.dvisor identified a pattern where the AroonDown red line was above 70 while the AroonUp green line was below 30 for three straight days. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options. A.I.dvisor looked at 231 similar instances where the Aroon Indicator formed such a pattern. In of the 231 cases the stock moved lower. This puts the odds of a downward move at .
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on June 18, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on OVID as a result. In of 97 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
OVID moved below its 50-day moving average on June 01, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for OVID crossed bearishly below the 50-day moving average on May 26, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In of 14 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where OVID declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 60 cases where OVID's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where OVID advanced for three days, in of 272 cases, the price rose further within the following month. The odds of a continued upward trend are .
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. OVID’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.118) is normal, around the industry mean (20.966). P/E Ratio (0.000) is within average values for comparable stocks, (36.007). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.690). OVID has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.038). P/S Ratio (28.409) is also within normal values, averaging (367.026).
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. OVID’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Provides medicines to children and adults with neurological disorders
Industry Biotechnology